Natixis Replimune Group, Inc. Transaction History
Natixis
- $17.6 Billion
- Q3 2024
Shares
2 transactions
Others Institutions Holding REPL
# of Institutions
149Shares Held
68MCall Options Held
52.3KPut Options Held
80.3K-
Baker Bros. Advisors LP New York, NY11MShares$155 Million1.3% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD9.88MShares$139 Million0.01% of portfolio
-
Fcpm Iii Services B.V. Naarden, P74.87MShares$68.4 Million9.16% of portfolio
-
Redmile Group, LLC San Francisco, CA4.78MShares$67.2 Million3.43% of portfolio
-
Black Rock Inc. New York, NY4.71MShares$66.2 Million0.0% of portfolio
About Replimune Group, Inc.
- Ticker REPL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,306,700
- Market Cap $693M
- Description
- Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...